|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005516,
umls-concept:C0007137,
umls-concept:C0017262,
umls-concept:C0185117,
umls-concept:C0205420,
umls-concept:C0332293,
umls-concept:C0460004,
umls-concept:C0681890,
umls-concept:C1333355,
umls-concept:C1559154,
umls-concept:C2911684
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-7-2
|
|
pubmed:abstractText |
The excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-limiting role in the nucleotide excision repair pathway and is associated with resistance to platinum-based chemotherapy. The purpose of this study was to evaluate the role of ERCC1 expression as a predictive marker of survival in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) treated with cisplatin-based concurrent chemoradiotherapy (CCRT). ERCC1 expression was assessed by immunohistochemical staining. The median age of the 45 patients analysed was 56 years (range 27-75 years), and 82% were men; 73% of all specimens showed high expression of ERCC1. The overall tumour response rate after CCRT was 89%. The median follow-up was 53.6 months (95% CI, 34.5-72.7 months). The 3-year progression-free survival (PFS) and overall survival (OS) rates were 58.7 and 61.3%, respectively. Univariate analyses showed that patients with low expression of ERCC1 had a significantly higher 3-year PFS (83.3 vs 49.4%, P=0.036) and OS (91.7 vs 45.5%, P=0.013) rates. Multivariate analysis showed that low expression of ERCC1 was an independent predictor for prolonged survival (HR, 0.120; 95% CI, 0.016-0.934, P=0.043). These results suggest that ERCC1 expression might be a useful predictive marker of locally advanced SCCHN in patients treated with cisplatin-based CCRT.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-10754494,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-11008208,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-11731512,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-12114432,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-12445742,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-14645636,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-15173087,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-15297394,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-15788669,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-16144923,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-16169122,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-16896002,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-16957145,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-16979838,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-17606717,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-8040325,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-8960133,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-9360634,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-9440758,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18594541-9632446
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1532-1827
|
|
pubmed:author |
pubmed-author:AhnY CYC,
pubmed-author:BaurJ RJR,
pubmed-author:ChoO KOK,
pubmed-author:HanJJ,
pubmed-author:JeongH-SHS,
pubmed-author:JinQ WQW,
pubmed-author:JunH JHJ,
pubmed-author:KimH SHS,
pubmed-author:LeeS KSK,
pubmed-author:ParkKK,
pubmed-author:YiS YSY
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
8
|
|
pubmed:volume |
99
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
167-72
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18594541-Adult,
pubmed-meshheading:18594541-Aged,
pubmed-meshheading:18594541-Antineoplastic Agents,
pubmed-meshheading:18594541-Carcinoma, Squamous Cell,
pubmed-meshheading:18594541-Cisplatin,
pubmed-meshheading:18594541-Combined Modality Therapy,
pubmed-meshheading:18594541-DNA-Binding Proteins,
pubmed-meshheading:18594541-Endonucleases,
pubmed-meshheading:18594541-Female,
pubmed-meshheading:18594541-Head and Neck Neoplasms,
pubmed-meshheading:18594541-Humans,
pubmed-meshheading:18594541-Immunohistochemistry,
pubmed-meshheading:18594541-Male,
pubmed-meshheading:18594541-Middle Aged,
pubmed-meshheading:18594541-Predictive Value of Tests,
pubmed-meshheading:18594541-Radiotherapy,
pubmed-meshheading:18594541-Survival Analysis
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation.
|
|
pubmed:affiliation |
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea.
|
|
pubmed:publicationType |
Journal Article
|
